Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib or dabrafenib + trametinib with radioactive iodine for RAI-refractory metastatic differentiated thyroid cancer with RAS or BRAFV600E mutation
2017-000742-21Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Jul 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of trametinib, dabrafenib + trametinib and thyrotropin alfa in well-differentiated thyroid cancer (WDTC) and thyroid cancer (2 cohorts), sponsored by Gustave Roussy. Primary endpoint: Objective response rate at 6 months. Started Jul 2017; status: completed.
02
Drugs
trametinibdabrafenib + trametinibthyrotropin alfa
03
Conditions
well-differentiated thyroid cancer (WDTC)thyroid cancer
Beyond the preview
Go deeper on 2017-000742-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000742-21.